BCRX
BioCryst Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -13.3% ·
share flow -12.2% ·
net new positions -15.4%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 109 | +4 | 139.04M | $1.39B | +8 | −4 |
| Q1 2026 | 108 | +4 | 130.67M | $1.24B | +14 | −10 |
| Q4 2025 | 103 | -1 | 127.11M | $991.41M | — | −1 |
| Q3 2025 | 22 | +2 | 89.66M | $680.51M | +2 | −1 |
| Q2 2025 | 18 | +1 | 80.75M | $723.56M | +1 | — |
| Q1 2025 | 14 | +1 | 26.41M | $198.06M | +1 | — |
| Q4 2024 | 13 | -2 | 21.17M | $159.22M | — | −2 |
| Q3 2024 | 14 | +4 | 16.62M | $126.32M | +4 | — |
| Q2 2024 | 10 | — | 15.77M | $97.44M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 7.50M | — | $56.39M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 4.82M | -0.3% | $36.28M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 4.82M | -0.3% | $36.28M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Fisher Asset Management ✦ | 3.18M | -4.7% | $23.93M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 1.77M | +0.8% | $13.34M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 839.27K | +6.6% | $6.31M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 839.27K | +6.6% | $6.31M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 839.27K | +6.6% | $6.31M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Millennium Management ✦ | 790.11K | -40.3% | $5.94M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 545.02K | -7.5% | $4.10M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 11 | Norges Bank ✦ (passive) | 524.80K | -14.2% | $3.95M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Arrowstreet Capital ✦ | 403.41K | -6.5% | $3.03M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 315.26K | +37.6% | $2.37M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 315.26K | +37.6% | $2.37M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 258.55K | -7.4% | $1.94M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 258.55K | -7.4% | $1.94M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 126.81K | -94.4% | $954,000 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | Wellington Management ✦ | 89.06K | -17.4% | $669,708 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Wellington Management ✦ | 89.06K | -17.4% | $669,708 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | Wellington Management ✦ | 89.06K | -17.4% | $669,708 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 21 | Wellington Management ✦ | 89.06K | -17.4% | $669,708 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Gotham Asset Management | $295,587 | was 0.0% |
| Marshall Wace | $252,753 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 298 holders, 245.96M shares, $2.30B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.